

# Pharmacogenomics implementation

“Can you implement if you don’t know if it works?” *Mary Violet Relling, 2014*

- Are we ‘discovering’ in the right context?
- Implementation is not discovery (but also needs high quality science)
  - What are we using the relevant endpoints?
  - Are the right people involved in the effort?
- Randomized Clinical Trials or organically randomized data from the clinic?
  - Can we get the necessary sample size by any other means?
  - Do we have the ‘right’ methods for optimizing data from the EHR?
  - Can we build iterative interventions into the EHR?
- Guidance for best-evidence-based therapy selection.

# PGRNSeq-Incidental Finding

Gene Symbol	Gene Name	Phen
<i>CACNA1S</i>	Calcium channel, voltage-dependent, L type, alpha 1S subunit	malignant l
<i>KCNH2</i>	Potassium voltage-gated channel, subfamily H (eag-related), member 2	long QT
<i>LDLR</i>	Low density lipoprotein receptor	hyperl
<i>RYR1</i>	Ryanodine receptor 1 (skeletal)	malignant l
<i>RYR2</i>	Ryanodine receptor 2 (cardiac)	catecholaminer ventricular
<i>SCN5A</i>	Sodium channel, voltage-gated,	long QT